Siemens Healthineers would like to thank AdMeTech and all its contributors for their dedication to the prevention, early detection, and treatment of prostate cancer.
We are committed to enabling and empowering healthcare providers in increasing value, by working together to develop unique solutions, supporting the delivery of personalized cancer care for patients. Our prostate cancer solutions help to provide accurate staging, diagnosis, planning and treatment decisions to facilitate optimal outcomes. From AI-powered digital solutions to innovative technologies in decision support1, image interpretation, and molecular imaging, we are with you at every step of the way.
AI-Pathway Companion1 Prostate Cancer for facilitating diagnosis and treatment decisions
Actionable insights for personalized care
Leveraging data integration and augmented intelligence technologies, AI-Pathway Companion with its applications, aims to support your multidisciplinary experts’ team to ease clinical and operational decisions. AI-Pathway Companion applications enable personalized and standardized patient management and offer process improvement insights through analysis of key performance indicators2. AI-Pathway Companion helps in patient-centric clinical and operational decisions along disease-specific care pathways using augmented intelligence, data integration, and insights from cohort analytics.
AI-Rad Companion3 Prostate MR application image annotation for urology and radiology biopsy support
Providing multi-modality imaging decision support
AI-Rad Companion Prostate MR supports in annotating images of the prostate gland for targeted MR/US-fusion biopsies and seamless information transfer to the urologist. Efficiency is gained as the AI-Rad Companion automatically segments the prostate gland, typically a tedious and time-consuming manual task. The radiologist can additionally mark potential targets for biopsy, reducing the risk for information loss.
Molecular Imaging in prostate cancer
The Value of Molecular Imaging for Prostate Cancer
Molecular imaging techniques noninvasively provide the biological characterization of prostate cancer that anatomical modalities lack. MI modalities assess physiological aberrations in cellular metabolism and the expression of various cellular surface proteins that occur in prostate cancer, providing a more accurate depiction of disease.